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A Response to Chief Justice Roberts: Why
Antitrust Must Play a Role in the Analysis
of Drug Patent Settlements
Michael A. Carrier*
The Supreme Court’s decision in FTC v. Actavis, Inc.1 has
justly received widespread attention for its antitrust analysis of
settlements by which brand-name drug companies pay generics
to delay entering the market. Much of the attention has focused
on the application of the Court’s standard and the logistics of
applying its rule of reason analysis to “reverse payment”
settlements.2
One overlooked issue, however, has been the position of
Chief Justice Roberts in dissent that the antitrust analysis of
these settlements must assume that the patent at issue is
invalid or not infringed, since these inquiries present a problem
of patent, not antitrust, law.
This Essay critiques Roberts’ position. After presenting his
argument, it explains that the dissent (1) presents an
incomplete view of patent policy; (2) downplays the significance
of antitrust law; and (3) ignores the Hatch-Waxman Act,
Congress’s resolution of the patent-antitrust intersection in the
pharmaceutical industry.
I.

ROBERTS’ ARGUMENT

A central concern with reverse payment settlements is that
a brand firm could pay a generic to delay entering the market
even though its patent is invalid or not infringed. In this

© 2014 Michael A. Carrier
* Distinguished Professor, Rutgers School of Law.
1. FTC v. Actavis, Inc., 133 S. Ct. 2223 (2013).
2. The term reveals a difference from typical licensing payments that
flow from challengers to patentees. See, e.g., Michael A. Carrier, Unsettling
Drug Patent Settlements: A Framework for Presumptive Illegality, 108 MICH.
L. REV. 37, 39 (2009).
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scenario, the conduct resembles market division, with two
competitors dividing the market and agreeing not to compete.3
Roberts recognized in his dissent in Actavis that “[t]he
problem” is that “we’re not quite certain if the patent is
actually valid, or if the competitor is infringing it.”4 But he then
swept these difficult issues under the patent rug by concluding
that “that is always the case, and is plainly a question of patent
law.”5
Roberts stated that a patentee’s “behavior would be
unlawful only if its patent were invalid or not infringed” and
that “the scope of the patent—i.e., what rights are conferred by
the patent—should be determined by reference to patent law.”6
He continued: “While it is conceivable to set up a legal system
where you assess the validity of patents or questions of
infringement by bringing an antitrust suit, neither the majority
nor the Government suggests that Congress has done so.”7
Roberts combined his exclusive preference for patent law
with the position that activity within the nominal scope of the
patent is immune from the antitrust laws. A patentee “acting
within the scope of its patent has an obvious defense to any
antitrust suit: that its patent allows it to engage in conduct
that would otherwise violate the antitrust laws.”8
Continuing the argument, Roberts lamented that the
majority “seems to have in mind a regime where courts ignore
the patent, and simply conduct an antitrust analysis of the
settlement without regard to the validity of the patent.”9 The
problem is that “a patent holder acting within the scope of its
patent does not engage in any unlawful anticompetitive
behavior” but “simply exercis[es] the monopoly rights granted
to it by the Government.”10
Relatedly, Roberts worried about applying antitrust law in
this
setting,
with
the
majority
inappropriately
“assess[ing] . . . patent law issues according to ‘antitrust

3.
4.
5.
6.
7.
8.
9.
10.

See, e.g., id. at 72.
Actavis, 133 S. Ct. at 2240 (Roberts, C.J., dissenting).
Id.
Id.
Id.
Id.
Id.
Id.
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policies.’”11 Similarly, the majority “says that any questions
regarding the legality of the settlement should be ‘measur[ed]’
by ‘procompetitive antitrust policies,’ rather than ‘patent law
policy.’”12
[A]lthough the question posed by this case is fundamentally a
question of patent law—i.e., whether Solvay’s patent was valid and
therefore permitted Solvay to pay competitors to honor the scope of
its patent—the majority declares that such questions should
henceforth be scrutinized by antitrust law’s unruly rule of reason.13

Finally, Roberts responded to the majority’s suggestion
that a right to settle “makes it harder to ‘eliminat[e]
unwarranted patent grants.’”14 He recognized that “[t]hat may
be so, but such a result—true of all patent settlements—is no
reason to adjudicate questions of patent law under antitrust
principles.”15 “[A]ntitrust law,” says Roberts, “has no business
prying into a patent settlement so long as that settlement
confers to the patent holder no monopoly power beyond what
the patent itself conferred—unless, of course, the patent was
invalid, but that again is a question of patent law, not antitrust
law.”16
II. CRITIQUE
Chief Justice Roberts’ dissent is subject to several
critiques. First, Roberts ignored the patent law policy of
challenging and eliminating invalid patents. Second, he
downplayed the role of antitrust law. And third, he neglected
the importance of the Hatch-Waxman Act, Congress’s
resolution of the patent-antitrust tradeoff in the
pharmaceutical industry.17

11. Id.
12. Id. at 2239 (quoting id. at 2231 (majority opinion)).
13. Id. at 2245.
14. Id. at 2243 (quoting id. at 2233 (majority opinion)).
15. Id.
16. Id.
17. Roberts also mischaracterized the majority’s position when he
lamented its use of antitrust “rather than” patent law to address reverse
payment settlements. Id. at 2240. The majority suggested not that antitrust
law replace patent law, but that it supplement it. Id. at 2231 (majority opinion)
(“[I]t would be incongruous to determine antitrust legality by measuring the
settlement’s anticompetitive effects solely against patent law policy, rather
than by measuring them against procompetitive antitrust policies as well.”
(emphasis added)).
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A. PATENT POLICY
Roberts claimed that the assessment of reverse payment
settlements should be conducted solely pursuant to patent law.
But even under this excessively constricted view, scrutiny is
warranted.
Patents are often viewed in absolute terms. They give a
blanket right to exclude. They are presumed valid. Any
incursion on their domain is inconsistent with the grant of the
right. But these assertions do not present the whole story.
Empirical studies have consistently shown that at least
40% of patents issued by the U.S. Patent and Trademark Office
(USPTO) that are litigated to decision are invalid,18 with one
FTC study finding that generics prevailed in 73% of challenges
between 1992 and 2000.19
These figures are not a surprise. The grant of a patent
reflects an initial judgment by the USPTO that an invention is
patentable. Such a judgment comes after limited scrutiny with
examiners having, on average, less than twenty hours to read
an application, search for prior art, evaluate patentability, and
reach and write up conclusions.20 Because of this limited

18. See John R. Allison & Mark A. Lemley, Empirical Evidence on the
Validity of Litigated Patents, 26 AIPLA Q.J. 185, 194, 205 (1998) (finding that
courts invalidated 46% of patents between 1989 and 1996); Kimberly A.
Moore, Judges, Juries, and Patent Cases—An Empirical Peek Inside the Black
Box, 99 MICH. L. REV. 365, 384–85 (2000) (finding that alleged infringers
prevailed in 42% of patent cases that reached trial between 1983 and 1999);
Decisions for 2000–2004, U. HOUS. L. CENTER, http://www.patstats.org/200004.htm (last visited Aug. 28, 2013) (stating that, in patent cases between 2000
and 2004, courts found 43% of patents invalid and 75% not infringed).
19. The study considered “Paragraph IV” certifications, by which generics
claim that patents are “invalid or will not be infringed by the generic drug.” 21
U.S.C. § 355(j)(2)(A)(vii)(IV) (2012); see infra note 51 and accompanying text.
FTC, GENERIC DRUG ENTRY PRIOR TO PATENT EXPIRATION: AN FTC STUDY
9–10,
16
(2002),
available
at
http://www.ftc.gov/os/2002/07/
genericdrugstudy.pdf. Portions of this and the next three paragraphs are
adapted from Brief Amici Curiae of 118 Law, Economics, and Business
Professors and the American Antitrust Institute in Support of Petitioners at
15–17, FTC v. Actavis, Inc., 133 S. Ct. 2233 (2013) (No. 12-416), 2013 WL
391001 [hereinafter Professor Brief].
20. FTC, TO PROMOTE INNOVATION: THE PROPER BALANCE OF
COMPETITION AND PATENT LAW AND POLICY 9–10 (2003), available at
http://www.ftc.gov/os/2003/10/innovationrpt.pdf.
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examination, litigation plays a crucial role in ensuring that
invalid patents do not block competition.21
The Actavis Court recognized the “patent-related policy of
eliminating unwarranted patent grants so the public will not
continually be required to pay tribute to would-be monopolists
without need or justification.”22 The Court had recognized,
more than four decades earlier in Lear, Inc. v. Adkins, that a
patent “simply represents a legal conclusion reached by the
Patent Office . . . in an ex parte proceeding, without the aid of
the arguments which could be advanced by parties interested
in proving patent invalidity.”23
Challenging invalid patents is even more important today
than it was at the time the Court decided Lear. The burdens on
the Patent Office have only increased, with the number of
patent applications skyrocketing to over 500,000 per year, more
than five times the number filed when Lear was decided.24
In short, even an exclusive focus on patent policy must
include the goal of testing (and eliminating) invalid patents
through litigation. Roberts’ suggestion to decide the issue solely
on grounds of patent law does not include this important aspect
of patent policy.

21. See Mark A. Lemley, Rational Ignorance at the Patent Office, 95 NW.
U. L. REV. 1495, 1531–32 (2001).
22. FTC v. Actavis, Inc., 133 S. Ct. 2223, 2233 (2013) (internal quotation
marks omitted).
23. Lear, Inc. v. Adkins, 395 U.S. 653, 670 (1969); see also Microsoft Corp.
v. i4i Ltd. P’ship, 131 S. Ct. 2238, 2253 (2011) (Breyer, J., concurring) (offering
measures designed to “increase the likelihood that discoveries or inventions
will not receive legal protection where none is due”); MedImmune, Inc. v.
Genentech, Inc., 549 U.S. 118, 137 (2007) (finding that licensees have standing
to challenge patent validity or infringement without repudiating their
licenses); United States v. Glaxo Group, Ltd., 410 U.S. 52, 57 (1973)
(emphasizing “public interest in free competition” in concluding that a licensee
in an antitrust suit “may attack the validity of the patent under which he is
licensed even though he has agreed not to do so in his license”); BlonderTongue Labs. v. Univ. of Ill. Found., 402 U.S. 313, 349–50 (1971) (allowing
alleged infringer to claim estoppel where patent was previously declared
invalid).
24. U.S. Patent Statistics Chart, Calendar Years 1963–2012, USPTO,
http://www.uspto.gov/web/offices/ac/ido/oeip/taf/us_stat.htm (last visited Aug.
28, 2013) (showing 576,763 total patent applications filed in 2012, compared to
104,357 in 1969).
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B. ANTITRUST POLICY
As the majority in Actavis recognized, reverse payment
settlements have the “potential for genuine adverse effects on
competition.”25 Of all the types of business activity subject to
the antitrust laws, agreements by which competitors divide
markets could be the most dangerous since “[m]arket division
restricts all competition between the parties on all grounds.”26
Reverse payment settlements result in generics dropping
patent challenges and, in exchange for significant payments,
agreeing to delay entry into the market.27 Because the brand
makes more by keeping the generic out of the market than the
two parties would receive by competing in the market, the
parties have an incentive to cede the market to the brand firm
and split the monopoly profits.28 The brand then can use a
portion of this additional profit from delayed competition to pay
the generic.
Reverse payments allow brands to delay entry longer than
they could based on the strength of the patent itself. An
agreement concerning the generic entry date, without any cash
payment, will normally reflect the odds of the parties’ success
in patent litigation: the more likely the patentee is to win the
case, the more it can rely on the patent itself to exclude
competition.29 But by paying generics to stay out of the market,
a brand is likely to gain additional exclusivity by
supplementing this entry-date agreement with payment.30 The
quid pro quo for the payment would appear to be the generic’s
agreement to stay out of the market beyond the expected entry
date resulting from litigation.31 As Justice Breyer explained:
“The payment in effect amounts to a purchase by the patentee
of the exclusive right to sell its product, a right it already
claims but would lose if the patent litigation were to continue

25. Actavis, 133 S. Ct. at 2234 (internal quotation marks omitted).
26. Professor Brief, supra note 19, at 11. Portions of this and the next two
paragraphs are adapted from Professor Brief, supra note 19, at 11–12.
27. See id. at 11.
28. See Carl Shapiro, Antitrust Limits to Patent Settlements, 34 RAND J.
ECON. 391, 407 (2003).
29. HERBERT HOVENKAMP ET AL., IP AND ANTITRUST: AN ANALYSIS OF
ANTITRUST PRINCIPLES APPLIED TO INTELLECTUAL PROPERTY LAW § 15.3, at
15-45 (2d ed. Supp. 2010).
30. Professor Brief, supra note 19, at 12.
31. Id.
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and the patent were held invalid or not infringed by the generic
product.”32
Finally, market power likely exists where there are reverse
payments. Again, as the Court understood: “[W]here a reverse
payment threatens to work unjustified anticompetitive harm,
the patentee likely possesses the power to bring that harm
about in practice.”33 At a minimum, the “size of the payment” is
“itself a strong indicator of power,” in other words, “the power
to charge prices higher than the competitive level.”34 And a
firm that lacks this power is not likely to pay “large sums” to
induce “others to stay out of its market.”35
Nor, finally, did the Supreme Court’s precedents bar
antitrust liability in this setting. As Roberts recognized, the
array of cases the Court decided in the early and middle part of
the twentieth century addressed conduct lying outside the
scope of the patent.36 But just because a settlement covering a
product outside the scope of the patent violates the antitrust
laws does not mean that one falling within the facial scope of
the patent is automatically valid.37 And courts can reflexively
conclude that the settlement falls within the scope of the
patent only by making the inappropriate assumptions that the
patent is valid and infringed.38
In short, antitrust policy is relevant in determining the
legality of agreements by which brand firms pay generics to
delay entry.

32. FTC v. Actavis, Inc., 133 S. Ct. 2223, 2234 (2013).
33. Id. at 2236 (citing 7 PHILLIP E. AREEDA & HERBERT HOVENKAMP,
ANTITRUST LAW ¶ 1503, at 392–93 (3d ed. 2012)).
34. Id. (internal quotation marks omitted) (citing 12 PHILLIP E. AREEDA &
HERBERT HOVENKAMP, ANTITRUST LAW ¶ 2046, at 351 (3d ed. 2012)).
35. Id.
36. Id. at 2241 (Roberts, C.J., dissenting) (“But each of those cases stands
for the same, uncontroversial point: that when a patent holder acts outside the
scope of its patent, it is no longer protected from antitrust scrutiny by the
patent.”).
37. Michael A. Carrier, Why the “Scope of the Patent” Test Cannot Solve
the Drug Patent Settlement Problem, 16 STAN. TECH. L. REV. 1, 5 (2012).
38. Actavis, 133 S. Ct. at 2231–32; Carrier, supra note 37, at 5–6
(explaining that the agreements “might or might not violate the antitrust
laws,” but that “[t]hat depends on whether the patent is valid” and “cannot be
determined by the mere existence of the patent”).
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C. HATCH-WAXMAN ACT POLICIES
As the Supreme Court has made clear, it is appropriate for
courts applying antitrust law to “be attuned to the particular
structure and circumstances of the industry at issue.”39
Congress resolved the tension between the patent and antitrust
laws in the pharmaceutical industry by enacting the HatchWaxman Act (the Act).40 Any analysis of reverse payment
settlements thus should at least consider the policies
underlying the Act.41
A central aspect of this complex regulatory regime was to
encourage generic entry.42 At the time of the Act, generic firms
needed to undertake lengthy, expensive trials to demonstrate
safety and effectiveness even though they had the same active
ingredients as brand drugs.43 Approval by the U.S. Food and
Drug Administration (FDA) took years, and because the
required tests constituted infringement, generics could not
even begin the process during the patent term.44 At the time
Congress enacted Hatch-Waxman, there was no generic on the
market for 150 brand-name drugs whose patents had already
expired.45 The Act’s drafters lamented the “practical extension”
of the patentee’s “monopoly position” beyond the expiration of
the patent,46 and sought to “make available more low cost
generic drugs.”47
The first tool the legislature created to accelerate generic
entry was the Abbreviated New Drug Application (ANDA)
process, which allowed generic firms to rely on the brand drug’s
safety and effectiveness studies and avoid the expensive and
lengthy new drug application process.48 Second, Congress
39. Verizon Commc’ns, Inc. v. Law Offices of Curtis V. Trinko, LLP, 540
U.S. 398, 411 (2004).
40. Professor Brief, supra note 19, at 5; see Drug Price Competition and
Patent Term Restoration (Hatch-Waxman) Act of 1984, Pub. L. No. 98-417, 98
Stat. 1585 (codified as amended in scattered sections of 15, 21, 28, and 35
U.S.C.).
41. Portions of this and the next three paragraphs are adapted from
Professor Brief, supra note 19, at 5–7, and Carrier, supra note 2, at 42–45.
42. See Carrier, supra note 2, at 41–42.
43. Id. at 42.
44. Id.
45. H.R. REP. NO. 98-857, pt. 1, at 17 (1984).
46. H.R. REP. NO. 98-857, pt. 2, at 4.
47. H.R. REP. NO. 98-857, pt. 1, at 14.
48. 21 U.S.C. § 355(j)(2)(A), (j)(8)(B) (2012).
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resuscitated the experimental use defense, exempting from
infringement the manufacture, use, or sale of a patented
invention for uses “reasonably related to the development and
submission of information” under a federal law regulating the
manufacture, use, or sale of drugs.49 Third, Congress increased
competition by creating a 180-day period of generic marketing
exclusivity, reserved for the first generic to certify that the
brand firm’s patent was invalid or not infringed and enter the
market before the patent expired.50 The Act specified four
avenues by which a generic could challenge a brand’s patent,
but only the “Paragraph IV” route, which anticipates entry
before the end of the patent term, received market
exclusivity.51
In addition to promoting generic competition, the Act
included several mechanisms to bolster incentives for brandfirm innovation. First, Congress increased the effective patent
life by extending the patent term, with the extension currently
amounting to half the time the drug is in clinical trials plus the
period spent awaiting FDA approval after trials.52 Second,
Congress granted an automatic thirty-month stay of FDA
approval for generic products if patent holders sue generic
filers within forty-five days.53 Finally, Congress provided for
periods of market exclusivity not based on patents, such as the
four-year exclusivity period for a drug with a new active
ingredient.54
Courts cannot effectively analyze reverse payment
agreements without considering the Hatch-Waxman Act. The
Act had a central purpose of encouraging challenges to invalid
or not infringed patents during the term of the patent to
encourage early market entry. Reverse payment settlements
directly contravene this goal by allowing brands to pay generics
for delayed market entry. Not only does such conduct flout the
patent policy of testing invalid patents and present significant
antitrust harm, but it also disregards the Hatch-Waxman Act
and the important public policy goal of increasing the number
of affordable generic medicines.
49.
50.
51.
52.
53.
54.

35 U.S.C. § 271(e)(1) (2006 & Supp. V 2011).
21 U.S.C. § 355(j)(5)(B)(iv).
Id.
35 U.S.C. § 156(c) (2006 & Supp. V 2011).
21 U.S.C. § 355(j)(5)(B)(iii).
Id. § 355(j)(5)(F)(ii).
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CONCLUSION
Chief Justice Roberts contended that in determining the
legality of reverse payment settlements, antitrust analysis
must assume that the patents at issue are valid and infringed.
But that position shortchanges patent law, which includes a
policy goal of testing invalid patents to make sure they do not
block competition. It downplays antitrust law’s role in
monitoring behavior that can resemble market division
between potential competitors. And it ignores the HatchWaxman Act’s encouragement of challenges to patents that are
invalid or not infringed.
In a nutshell, the appropriate antitrust treatment of
reverse payment settlements is more nuanced than the version
presented by Roberts.

